AT2 Receptor Antagonist Drug-Coated Stent for Aortic Wall Strengthening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current medical devices lack effective solutions for preventing and treating aortic aneurysms and aortic dissections, as they do not adequately address the progression and weakening of the aorta wall due to connective tissue destruction and vascular remodeling issues.
Innovation Solution
An implantable medical device incorporating angiotensin II type 2 (AT2) receptor antagonist compounds is used, which is releasably associated with a stent or stent graft, providing a controlled release of the compound to mitigate further progression and strengthen the aorta wall.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional implantable medical devices are used to treat aortic aneurysms, then structural support is provided, but the progression of aorta wall weakening due to connective tissue destruction is not effectively prevented
Solution Approach 1:
The patent combines a stent structure with an integrated drug delivery system, merging mechanical support function with pharmacological treatment. The stent serves both as a structural support device and as a carrier for controlled release of AT2 receptor antagonist compounds, addressing both mechanical and biological aspects of aneurysm treatment simultaneously.
Solution Approach 2:
The patent introduces AT2 receptor antagonist compounds as intermediary substances that mediate the treatment effect. These compounds act as biochemical intermediaries between the device and the aorta wall tissue, preventing connective tissue destruction through pharmacological action while the stent provides mechanical support.
2Strength
If the aorta wall continues to degrade from connective tissue breakdown, then aneurysm progression occurs, but existing devices do not adequately strengthen the aorta wall
Solution Approach 1:
The patent applies preliminary anti-action by using AT2 receptor antagonist compounds to prevent connective tissue destruction before it can cause significant weakening. The drug is released in advance to inhibit matrix metalloproteinases and prevent elastin breakdown, countering the harmful degradative processes before they can compromise aorta wall strength.
Solution Approach 2:
The patent changes the biochemical parameters of the aorta wall environment by introducing AT2 receptor antagonist compounds that alter the molecular mechanisms of tissue degradation. This pharmacological intervention changes the chemical and biological parameters governing connective tissue integrity, preventing the cascade of degradation that leads to aneurysm formation.
3Quantity of substance
If systemic medication is used to treat aortic disease, then broad coverage is achieved, but localized delivery to the aneurysm site is insufficient
Solution Approach 1:
The patent applies local quality by concentrating the AT2 receptor antagonist compounds specifically at the aneurysm site through the stent's integrated drug delivery system. This localized delivery ensures high drug concentration precisely where needed in the affected aorta wall tissue, rather than distributing medication systemically throughout the body.
Solution Approach 2:
The stent structure provides self-service drug delivery by incorporating the medication directly into its structure. The device automatically releases the AT2 receptor antagonist compounds at the implantation site through controlled release mechanisms, eliminating the need for separate systemic administration and ensuring precise local delivery.
Data Source
AI summary
This invention relates to medical devices and an angiotensin II type 2 (AT2) receptor antagonist compound, the medical device being adapted to release the AT2 receptor antagonist compound within a body of a patient. This invention also relates to medical devices and methods of treatment of disease, such as aneurysms and aortic dissection. Medical devices may include coated stents, grafts, stent grafts, balloons and catheters.